Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases.
Clopidogrel has been reported to be safe and effective in reducing vascular events. Nevertheless, there is growing evidence that clopidogrel may cause thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome (TTP/HUS). This association has been debated, since in several cases alternative causes could not be excluded. Two new cases of TTP/HUS associated with clopidogrel are reported here. After discontinuation of clopidogrel and treatment with plasma exchange, both patients had a complete and sustained recovery from TTP/HUS. These cases corroborate previous observations that clopidogrel may indeed be a rare cause of TTP/HUS.
Institute of Clinical Pharmacology, Charité-University Medicine, Campus Charité Mitte, Schumannstrasse 20/21, 10117 Berlin, Germany. frank.andersohn@charite.de
F
F
Andersohn
F G
FG
Hagmann
E
E
Garbe
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy; D002343:Carotid Artery, Internal; D016893:Carotid Stenosis / Q000188:drug therapy; D000077144:Clopidogrel; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced*; D013988:Ticlopidine / Q000009:adverse effects* / Q000031:analogs & derivatives*
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine